|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 20.50 | ACUITE D | Reaffirmed | Issuer not co-operating* | - |
| Total Outstanding | 20.50 | - | - |
| Total Withdrawn | 0.00 | - | - |
| * The issuer did not co-operate; based on best available information. | |||
|
Rating Rationale |
|
Acuité has reaffirmed the long-term rating of ‘ACUITE D’ (read as ACUITE D) on the Rs. 20.50 crore bank facilities of Vacc-Syn Biotech Private Limited (VBPL). The rating continues to be flagged as “Issuer Not-Cooperating” and is based on best available information. |
| About the Company |
|
Vacc-Syn Biotech Private Limited, incorporated in 2007, is a Thane based company engaged in the manufacturing of serum antisnake venom, anti-tetanus and anti-rabies. The company is led by Mr. Sanjay Bawsay and Mrs. Madhavi Bawsay, commenced commercial production in January, 2014 at its manufacturing facility at Badlapur, Maharashtra. |
| Unsupported Rating |
| Not Applicable |
| Non-cooperation by the issuer/borrower: |
|
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
| Limitation regarding information availability |
| Rating Sensitivity |
| "No information provided by the issuer / available for Acuite to comment upon." |
| Liquidity Position |
| "No information provided by the issuer / available for Acuite to comment upon." |
| Outlook |
| Not Applicable |
| Other Factors affecting Rating |
|
None
|
| Particulars | Unit | FY 18 (Actual) | FY 17 (Actual) |
| Operating Income | Rs. Cr. | 0.28 | 3.51 |
| PAT | Rs. Cr. | (12.06) | (1.27) |
| PAT Margin | (%) | (4237.28) | (36.15) |
| Total Debt/Tangible Net Worth | Times | (2.37) | 11.80 |
| PBDIT/Interest | Times | (3.59) | 0.86 |
| Status of non-cooperation with previous CRA |
| Not Applicable |
| Any other information |
| None |
| Applicable Criteria |
|
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on complexity levels of the rated instrument |
|
|||||||||||||||||||||||||||||||||||||
| |
|
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| * The issuer did not co-operate; based on best available information. | |||||||||||||||||||||||||||
Disclosure of list of non-cooperative issuers |
|
• Listed :- https://www.acuite.in/Non-Cooperative_Issuer_Listed.php • Unlisted :- https://www.acuite.in/Non-Cooperative_Issuer_Unlisted.php |
|
Contacts |
About Acuité Ratings & Research |
| © Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |
